Alzheimer's Disease: Biomarker and Treatment Advances with Access Barriers

Rapid progress in anti-amyloid and tau-targeting therapies, blood biomarkers (pTau217, TOBY urine test), and new insights into sex differences (X chromosome study, estrogen therapy reduces amyloid). Voyager's dual tau-targeted approach (antibody and gene therapy) advancing to first-in-human Q4 2026. GLP-1 RAs show neuroprotective potential but unproven in established AD. However, only 15,000 of 1M eligible Americans have received FDA-approved treatments due to insurance and screening barriers. Rethinking dementia diagnosis beyond memory loss critical for accessing DMTs.